Role of HER2/HER3 co-receptor in breast carcinogenesis

Future Oncology

Volumn 1, Issue 6, 2005, Pages 841-849

  Way, Tzong Der ^a   Lin, Jen Kun ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Akt; apigenin; apoptosis; breast cancer; HER2; HER3; PI3K; proteasome

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3;

BREAST TUMOR; DIMERIZATION; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; DIMERIZATION; HUMANS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 33845720433     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.1.6.841     Document Type: Review

References (72)

1. Alessi DR, Cohen P: Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 8(1), 55-62 (1998).
2. Schally AV, Comaru-Schally AM: in Cancer Medicine. Dekker, Hamilton, ON, 5th Ed., 715-729 (2000).
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987).
4. Menard S, Tagliabue E, Campiglio M, Pupa SM: Role of HER2 gene overexpression in breast carcinoma. J. Cell Physiol. 182(2), 150-162 (2000).
5. Yu DH, Hung MC: Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 6(11), 1991-1996 (1991).
6. Yu DH, Wang SS, Dulski KM, Nicolson, GL, Hung MC: c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res. 54(12), 3150-3156 (1994).
7. Yusa K, Sugimot Y, Yamori T, Yamamoto T, Toyoshima K, Tsuruo T: Low metastatic potential of clone from murine colon adenocarcinoma 26 increased by transfection of activated c-erbB-2 gene. J. Natl. Cancer Inst. 82(20), 1632-1635 (1990).
8. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2(2), 127-137 (2001).
9. Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19(13), 3159-3167 (2000).
10. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL 3rd: Insect cellexpressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl Acad. Sci. USA 91(17), 8132-8136 (1994).
11. Sierke SL, Cheng K, Kim HH, Koland JG.: Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem. J. 322(Pt3), 757-763 (1997).
12. Kim HH, Sierke SL, Koland JG: Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J. Biol. Chem. 269(40), 24747-24755 (1994).
13. Soltoff SP, Carraway KL 3rd, Prigent SA, Gullick WG, Cantley LC: ErbB3 is involved in activation of phosphatidylinositol 3- kinase by epidermal growth factor. Mol. Cell. Biol. 14(6), 3550-3558 (1994).
14. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A: Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 14(17), 4267-4275 (1995).
15. Sliwkowski MX, Schaefer G, Akita RW et al.: Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269(20), 14661-14665 (1994).
16. Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y: Neu differentiation factor neuregulin isoforms activate distinct receptor combinations. J. Biol. Chem. 271(32), 19029-19032 (1996).
17. Carraway KL 3rd, Soltoff SP, Diamonti AJ, Cantley LC: Heregulin stimulates mitogenesis and phosphatidylinositol 3- kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J. Biol. Chem. 270(13), 7111-7116 (1995).
18. Cohen BD, Kiener PA, Green JM, Foy L, Fell HP, Zhang K: The relationship between human epidermal growth factor-like receptor expression and cellular transformation in NIH 3T3 cells. J. Biol. Chem. 271(48), 30897-30903 (1996).
19. Zhang K, Sun JL, Liu NL et al.: Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 271(7), 3884-3890 (1996).
20. Alimandi M, Romano A, Curia MC et al.: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10(9), 1813-1821 (1995).
21. Siegel PM, Siegel ED, Cardiff RD, Muller WJ: Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 18(8), 2149-2164 (1999).
22. Kim A, Liu B, Ordonez-Ercan D et al.: Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Breast Cancer Res. 7(5), R708-R718 (2005).
23. Way TD, Kao MC, Lin JK: Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neuoverexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Aktdependent pathway. J. Biol. Chem. 279(6), 4479-4489 (2004).
24. Aroian RV, Koga M, Mendel JE, Ohshima Y, Sternberg PW: The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily. Nature 348(6303), 693-699 (1990).
25. Freeman M: Complexity of EGF receptor signalling revealed in Drosophila. Curr. Opin. Genet. Dev. 8(4), 407-411 (1998).
26. Tzahar E, Yarden Y: The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim. Biophys. Acta 1377(1), M25-M37 (1998).
27. Yarden Y: The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37(Suppl. 4), S3-S8 (2001).
28. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of the human cerbB-2 gene: a 185- kilodalton glycoprotein with tyrosine kinase activity. Science 232(4758), 1644-1646 (1986).
29. van der Geer P, Hunter T, Lindberg RA: Receptor protein-tyrosine kinases and their signal transduction pathways. Ann. Rev. Cell Biol. 10, 251-337 (1994).
30. Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta Rev. Cancer 1198(2-3), 165-184 (1994).
31. Stein RA, Staros JV: Evolutionary analysis of the ErbB receptor and ligand families. J. Mol. Evol. 50(5), 397-412 (2000).
32. Rubin I, Yarden Y: The basic biology of HER2. Ann. Oncol. 12(Suppl. 1), S3-S8 (2001).
33. Pinkas-Kramarski R, Soussan L, Waterman H et al.: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15(10), 2452-2467 (1996).
34. Klapper LN, Glathe S, Vaisman N et al.: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl Acad. Sci. USA 96(9), 4995-5000 (1999).
35. Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16(7), 1647-1655 (1997).
36. Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE: ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol. Cell Biol. 18(9), 5042-5051 (1998).
37. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 8(1), 11-31 (2001).
38. Hackel PO, Zwick E, Prenzel N, Ullrich A: Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 11(2), 184-189 (1990).
39. Hellyer NJ, Cheng K, Koland JG: ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem. J. 333(Pt3), 757-763 (1998).
40. Prigent SA, Gullick WJ: Identification of c-erbB-3 binding sites for phosphatidylinositol 3-kinase and SHC using an EGF receptor/cerbB-3 chimera. EMBO J. 13(12), 2831-2841 (1994).
41. Hellyer NJ, Kim MS, Koland JG: Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 coreceptor. J. Biol. Chem. 276(45), 42153-42161 (2001).
42. Downward J: Lipid-regulated kinases: some common themes at last. Science 279(5351), 673-674 (1998).
43. Datta SR, Dudek H, Tao X et al.: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91(2), 231-241 (1997).
44. Cardone MH, Roy N, Stennicke HR et al.: Regulation of cell death protease caspase-9 by phosphorylation. Science 282(5392), 1318-1321 (1998).
45. Brunet A, Bonni A, Zigmond MJ et al.: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96(6), 857-868 (1999).
46. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-B activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401(6748), 82-85 (1999).
47. Romashkova JA, Makarov SS: NF-B is a target of AKT in antiapoptotic PDGF signalling. Nature 401(6748), 86-90 (1999).
48. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN: Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc. Natl Acad. Sci. USA 94(8), 3627-3632 (1997).
49. Medema RH, Kops GJ, Bos JL, Burgering BM: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404(6779), 782-787 (2000).
50. Lemoine NR, Barnes DM, Hollywood DP et al.: Expression of the c-erbB3 gene product in breast cancer. Br. J. Cancer 66(6), 1116-1121 (1992).
51. Rajkumar T, Stamp GWH, Pandha HS, Waxman J, Gullick WJ: Expression of the type 1 tyrosine kinase growth factor EGF receptors c-erbB-2 and c-erbB-3 in bladder cancer. J. Pathol. 179(4), 381-385 (1996).
52. Wiseman SM, Makretsov N, Nielsen TO et al.: Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 103(9), 1770-1777 (2005).
53. Bodey B, Bodey B Jr, Groger AM et al.: Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res. 17(2B), 1319-1330 (1997).
54. Alimandi M, Romano A, Curia MC et al.: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation. Oncogene 10(9), 1813-1821 (1995).
55. Beerli RR, Wels W, Hynes NE: Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. Biol. Chem. 269(39), 23931-23936 (1994).
56. Neve RM, Sutterlüty H, Pullen N et al.: Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 19(13), 1647-1656 (2000).
57. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13(12), 1501-1512 (1999).
58. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE: ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1/Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol. 20(9), 3210-3223 (2000).
59. Venter DJ, Tuzi NL, Kumar S, Gullick WJ: Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 2(8550), 69-72 (1987).
60. Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13(1), 63-72 (1996).
61. Allred DC, Clarke GM, Molina R et al.: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum. Pathol. 23(9), 974-979 (1992).
62. Alimandi M, Romano A, Curia MC et al.: Cooperative signaling of erbB3 and erbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10(9), 1813-1821 (1985).
63. Klapper LN, Waterman H, Sela M, Yarden Y: Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60(13), 3384-3388 (2000).
64. Levkowitz G, Klapper LN, Harari D, Lavi S, Sela M, Yarden Y: c-Cbl is a suppressor of the neu oncogene. J. Biol. Chem. 275(45), 35532-35539 (2000).
65. Miller P, DiOrio C, Moyer M et al.: Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res. 54(10), 2724-2730 (1994).
66. Mimnaugh EG, Chavany C, Neckers L: Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 271(37), 22796-22801 (1996).
67. Neckers L, Schulte TW, Mimnaugh E: Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest. New Drugs 17(4), 361-373 (1999).
68. Rose DP, Boyar AP, Wynder EL: International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer 58(11), 2363-2371 (1986).
69. Kuo ML, Lee KC, Lin JK: Genotoxicities of nitropyrenes and their modulation by apigenin, tannic acid, ellagic acid and indole-3-carbinol in the Salmonella and CHO systems. Mutat. Res. 270(2), 87-95 (1992).
70. Chaumontet C, Bex V, Gaillard-Sanchez I, Seillan-Heberden C, Suschetet M, Martel P: Apigenin and tangeretin enhance gap junctional intercellular communication in rat liver epithelial cells. Carcinogenesis 15(10), 2325-2330 (1994).
71. Kuo ML, Yang NC: Reversion of v-H-rastransformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. Biochem. Biophys. Res. Commun. 212(3), 767-775 (1995).
72. Way TD, Kao MC, Lin JK: Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/neu-overexpressing breast cancer cells. FEBS Lett. 579(1), 145-152 (2005).